Movement Alert｜ImmunityBio Falls 5.23% in Regular Trading, Profit-Taking Continues After Multiple Catalysts Priced In

Market Focus05-22

On May 22, ImmunityBio fell 5.23% in regular trading, trading at $7.3285/share, with trading volume of $20.50 million. The stock has now declined for a second consecutive session following a 7.89% drop on May 21, as investors continue to take profits after a series of positive catalysts were rapidly priced in.

The selloff comes despite a dense cluster of fundamental developments. On May 17, the company signed an exclusive US agreement with Japan BCG Laboratory to import and commercialize the Tokyo-172 BCG strain for bladder cancer treatment. On May 18, ImmunityBio announced it received five US patents covering its ANKTIVA plus BCG combination therapy, valid through at least 2035. Additionally, at the AUA annual meeting on May 19, the company presented favorable efficacy comparison data for its Nai+BCG regimen versus Nadofaragene and TAR-200 in complete response rates.

Trading volume contracted notably from the prior session's $52.14 million, suggesting selling pressure is easing but buy-side conviction remains weak as the market digests the concentrated wave of positive news.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158674572?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 22:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158674572","market":"us","top_or_hot":-1,"title":"Movement Alert｜ImmunityBio Falls 5.23% in Regular Trading, Profit-Taking Continues After Multiple Catalysts Priced In","media":"Market Focus","content":"<p><p>On May 22, ImmunityBio fell 5.23% in regular trading, trading at $7.3285/share, with trading volume of $20.50 million. The stock has now declined for a second consecutive session following a 7.89% drop on May 21, as investors continue to take profits after a series of positive catalysts were rapidly priced in.</p><p>The selloff comes despite a dense cluster of fundamental developments. On May 17, the company signed an exclusive US agreement with Japan BCG Laboratory to import and commercialize the Tokyo-172 BCG strain for bladder cancer treatment. On May 18, ImmunityBio announced it received five US patents covering its ANKTIVA plus BCG combination therapy, valid through at least 2035. Additionally, at the AUA annual meeting on May 19, the company presented favorable efficacy comparison data for its Nai+BCG regimen versus Nadofaragene and TAR-200 in complete response rates.</p><p>Trading volume contracted notably from the prior session's $52.14 million, suggesting selling pressure is easing but buy-side conviction remains weak as the market digests the concentrated wave of positive news.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ImmunityBio Falls 5.23% in Regular Trading, Profit-Taking Continues After Multiple Catalysts Priced In</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ImmunityBio Falls 5.23% in Regular Trading, Profit-Taking Continues After Multiple Catalysts Priced In\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-22 22:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 22, ImmunityBio fell 5.23% in regular trading, trading at $7.3285/share, with trading volume of $20.50 million. The stock has now declined for a second consecutive session following a 7.89% drop on May 21, as investors continue to take profits after a series of positive catalysts were rapidly priced in.</p><p>The selloff comes despite a dense cluster of fundamental developments. On May 17, the company signed an exclusive US agreement with Japan BCG Laboratory to import and commercialize the Tokyo-172 BCG strain for bladder cancer treatment. On May 18, ImmunityBio announced it received five US patents covering its ANKTIVA plus BCG combination therapy, valid through at least 2035. Additionally, at the AUA annual meeting on May 19, the company presented favorable efficacy comparison data for its Nai+BCG regimen versus Nadofaragene and TAR-200 in complete response rates.</p><p>Trading volume contracted notably from the prior session's $52.14 million, suggesting selling pressure is easing but buy-side conviction remains weak as the market digests the concentrated wave of positive news.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1158674572","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158674572","pubTimestamp":1779458787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 22, ImmunityBio fell 5.23% in regular trading, trading at $7.3285/share, with trading volume of $20.50 million. The stock has now declined for a second consecutive session following a 7.89%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"动静提示|ImmunityBio常规交易跌5.23%多重催化剂定价后获利了结持续","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"On May 22, ImmunityBio fell 5.23% in regular trading, trading at $7.3285/share, with trading volume of $20.50 million. The stock has now declined for a second consecutive session following a 7.89% drop on May 21, as investors continue to take profits after a series of positive catalysts were rapidly priced in.The selloff comes despite a dense cluster of fundamental developments. On May 17, the company signed an exclusive US agreement with Japan BCG Laboratory to import and commercialize the Tokyo-172 BCG strain for bladder cancer treatment. On May 18, ImmunityBio announced it received five US patents covering its ANKTIVA plus BCG combination therapy, valid through at least 2035. Additionally, at the AUA annual meeting on May 19, the company presented favorable efficacy comparison data for its Nai+BCG regimen versus Nadofaragene and TAR-200 in complete response rates.Trading volume contracted notably from the prior session's $52.14 million, suggesting selling pressure is easing but buy-side conviction remains weak as the market digests the concentrated wave of positive news.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158674572","isCrawlerRequest":true}